Table 4.
Obese patients with normo-glycemic condition treated by a hypocaloric diet (group 3).
| Study variables | Group 3 (n 18) at baseline | Group 3 (n 18) at 12 months of follow-up | P-value |
|---|---|---|---|
| CLINICAL VARIABLES | |||
| BMI (Kg/m2) | 33.7 ± 2.4 | 31.7 ± 0.6 | / |
| Systolicarterial pressure (mmHg) | 126 ± 10.3 | 124 ± 8.8 | / |
| Diastolicarterial pressure (mmHg) | 85 ± 2.1 | 75 ± 2.3 | / |
| Heart rate (beats for minute) | 69 ± 8 | 66 ± 7 | / |
| WHR | 0.91 ± 0.001 | 0.81 ± 0.001 | / |
| HOMA-IR | 4.1 ± 0.28 | 4.1 ± 0.28 | / |
| Insulin(μU/ml) | 22.6 ± 1.9 | 23.1 ± 1.6 | / |
| Glucose (mmol/L) | 5.34 ± 0.57 | 5.32 ± 0.59 | / |
| Cholesterol(mmol/L) | 4.66 ± 1.02 | 4.14 ± 0.81 | <0.05° |
| HDL(mmol/L) | 1.78 ± 0.41 | 1.78 ± 0.41 | / |
| LDL (mmol/L) | 3.17 ± 0.59 | 3.11 ± 0.57 | / |
| Triglycerides(mmol/L) | 1.61 ± 0.31 | 1.62 ± 0.67 | / |
| Creatinine (mmol/L) | 78.3 ± 2.6 | 74.8 ± 1.8 | / |
| BIOHUMORAL MARKERS | |||
| CRP (mmol/L) | 0.85 ± 0.38 | 0.48 ± 0.01 | <0.05° |
| IL6 (pg/ml) | 3.53 ± 0.43 | 3.13 ± 0.43 | <0.05° |
| TNFα (pg/ml) | 5.51 ± 1.09 | 4.76 ± 0.79 | <0.05° |
| Nitrotyrosine (nmol/l) | 1, 211±0, 205 | 0, 917±0, 251 | <0.05° |
| ECHOCARDIOGRAPHICPARAMETERS | |||
| Intima-media tickness (mm) | 0.85 ± 0.14 | 0.83 ± 0.15 | / |
| LVTDd (mm) | 54 ± 4.6 | 53 ± 4.1 | / |
| LVTSd (mm) | 31 ± 6.7 | 29 ± 6.7 | / |
| LVEF (%) | 53 ± 6 | 55 ± 5 | / |
| LAD (mm) | 42 ± 2 | 41 ± 2 | / |
| Septum (mm) | 13.5 ± 2.6 | 10 ± 2 | <0.05° |
| Posteriorwall (mm) | 11 ± 1 | 8.5 ± 1 | <0.05° |
| MPI | 0.57 ± 0.03 | 0.37 ± 0.02 | <0.05° |
| LV mass (g) | 203.7 ± 48.4 | 129.2 ± 33.1 | <0.05° |
| LV mass/BSA (g/m2) | 90.13 ± 21.42 | 57.17 ± 14.64 | <0.05° |
| LV mass/h (m2) | 72.23 ± 17.16 | 45.81 ± 11.73 | <0.05° |
Clinical characteristics of obese patients with normo-glycemic condition (group 3) at baseline vs. 12 months of follow-up. In this table are reported the study variables of group 3, 18 obese patients with normo glycemic condition treated by a hypocaloric diet. In the study the variables (first column to the left) reported are clinical variables, biohumoral markers, and echocardiographic parameters for each group of patients. We reported fasting glucose and lipid values. CRP, C reactive protein; g, grams; m, meters; h, height; HOMA_IR, homeostasis model for the assessment of insulin resistance; IL6, interleukine 6; LAD, left atrium diameter; LV, left ventricle; LVEF, left ventricle ejection fraction; LVTDd, left ventricle telediastolic diameter; LVTDs, left ventricle telesystolic diameter; MPI, myocardium performance index; TNFα, tumor necrosis factor alpha; WHR, waist hip ratio. The symbol symbol
is indicating the p <0.05 with the comparison of group 3 at baseline vs. group 3 at 12 months follow-up.